CURRENT STATUS
Obesity medicine has been transformed in under five years. Incretin-based therapy redefined what pharmacology can achieve: semaglutide delivers ~15% mean weight loss and tirzepatide up to ~22.5%, approaching bariatric-surgery outcomes, while the SELECT trial reframed treatment as cardiovascular prevention by cutting major adverse cardiovascular events ~20% in people without diabetes. The frontier is now durability and body composition — triple agonists (retatrutide) pushing past 24%, muscle-sparing combinations preserving lean mass, oral agents removing the injection barrier, and gene therapy for the ~5% with monogenic disease. The unresolved truth: current drugs manage a defended weight set-point rather than resetting it.
KEY BREAKTHROUGHS
Semaglutide (Wegovy/Ozempic) — GLP-1 agonist achieving ~15% sustained weight loss
Tirzepatide (Mounjaro/Zepbound) — dual GIP/GLP-1 agonist achieving ~22% weight loss
Amgen MariTide — monthly injection GLP-1/GIP dual antagonist in Phase II
Retatrutide — triple agonist (GLP-1/GIP/glucagon) showing 24% weight loss in Phase II
AI-COMPRESSED PIPELINE
AI TOOLS ACCELERATING CURES
KEY ORGANIZATIONS
KEY CLINICAL TRIALS
TRIUMPH-3 — Retatrutide in Obesity With Cardiovascular Disease (Phase 3)
ViewEli Lilly
A triple hormone agonist (GLP-1 + GIP + glucagon) tested in adults with obesity and established cardiovascular disease. Phase 2 data showed ~24% average weight loss — approaching bariatric-surgery territory from a weekly injection.
Retatrutide in Obesity Without Type 2 Diabetes (Phase 3)
ViewEli Lilly
Part of the TRIUMPH program evaluating retatrutide for weight management in people who are overweight or obese without diabetes, tracking durable weight loss and metabolic health improvements.
TIMELINE ESTIMATE
Next-gen & oral incretins: 1–3 years. Muscle-sparing combinations: 3–5 years. Gene therapy for monogenic obesity: 4–6 years. Full metabolic reprogramming: 6–10 years.